• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-09-02

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that accumulates in lysosomes, activates AMPKα, and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects oxysterol compartmentalization with T-cell exclusion and shows that targeting CH25H can improve antitumor immunity, including responses to anti-PD-1 therapy.

• Z-Ligustilide and PLPP1 in Cisplatin Resistance

  2026-09-01

  This preprint proposes that Z-ligustilide restores cisplatin sensitivity in resistant lung cancer cells by increasing PLPP1-associated phospholipid remodeling, lowering PIP3–AKT signaling, and promoting cell-cycle arrest and apoptosis. Its combination of metabolomics, transcriptomics, perturbation experiments, and clinical association analyses provides a mechanistic framework, although the findings require validation beyond the reported cell models and non-peer-reviewed study.

• FLAG Tag Peptide: From Epitope to Translation

  2026-09-01

  A mechanistic and strategic guide to using the FLAG tag Peptide (DYKDDDDK) for recombinant protein detection, affinity elution, and translational assay design. The article connects peptide-based purification logic with antibody-binding kinetics while defining practical boundaries for 1X and 3X FLAG workflows.

• Vernakalant Hydrochloride: From Channels to Conversion

  2026-08-31

  A translational analysis of RSD1235 that connects atrial ion-channel pharmacology, experimental validation, exposure-response modeling, and the strategic design of rapid atrial fibrillation studies.

• Quinolone–Coumarin Hybrids Against Toxoplasma gondii

  2026-08-31

  This 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolone and novobiocin scaffolds against intracellular Toxoplasma gondii. QC1, QC3, QC6, and novobiocin showed the most favorable balance of antiparasitic activity and host-cell tolerance, supporting scaffold hybridization as a source of new anti-Toxoplasma leads while highlighting the limits of translating antibacterial activity directly into antiparasitic efficacy.

• 2',7'-Dichlorofluorescein diacetate: ROS Guide

  2026-08-30

  Build a practical intracellular ROS measurement workflow with 2',7'-Dichlorofluorescein diacetate across microscopy, flow cytometry, and plate assays. The guide also explains how to use this broad redox readout to interrogate ROS-responsive nanocarriers without overstating what the fluorescence signal proves.

• EdU Flow Cytometry Assay Kits (Cy5) Guide

  2026-08-29

  EdU Flow Cytometry Assay Kits (Cy5) provide an endpoint method for quantifying DNA synthesis during S phase by labeling incorporated EdU with a Cy5 azide through copper-catalyzed click chemistry. The assay is suited to fixed-cell flow cytometry, cell-cycle analysis, and treatment-response studies, but not to live-cell imaging or workflows that cannot tolerate copper-catalyzed chemistry.

• H 89 2HCl: From PKA Mechanism to Translation

  2026-08-28

  A mechanistic and strategic guide to using H 89 2HCl for interrogating cAMP/PKA signaling, neuronal calcium dynamics, protein phosphorylation, and translational assay design.

• From DEVD Signal to Translational Apoptosis Insight

  2026-08-28

  A mechanistic and strategic guide to using DEVD-dependent caspase-3 activity as a functional bridge between cell-death biology, assay validation, and translational decision-making.

• Ibrexafungerp: From MICs to In Vivo Evidence

  2026-08-27

  Ibrexafungerp, also known as MK 3118, links a distinct glucan-synthase mechanism with oral exposure and activity against resistant Candida. This article explains how susceptibility assays and delayed-treatment animal models improve translational interpretation.

• PEP, cGAS–STING, and Healthy Aging

  2026-08-27

  The reference study identifies phosphoenolpyruvate (PEP) as an age-responsive glycolytic metabolite that restrains cGAS–STING-driven inflammation. Its longitudinal, mechanistic, and disease-model evidence connects metabolic state with inflammaging while also showing why PEP findings should not be directly equated with evidence for hexose diphosphate.

• SNS-032: Reading CDK9 and RNA Pol II Signals

  2026-08-26

  SNS-032 (BMS-387032) is a selective CDK2, CDK7, and CDK9 inhibitor whose RNA Pol II phosphorylation profile can connect kinase engagement with transcriptional and cancer phenotypes. This article develops an assay-centered framework and carefully distinguishes SNS-032 evidence from related CDK9 findings in SARS-CoV-2 research.

• EDTA-Free Protease Inhibitor for OXPHOS Assays

  2026-08-26

  Discover how a Protease Inhibitor Cocktail supports reliable OXPHOS cancer assays by preserving protein integrity during extraction. This guide connects EDTA-free protease control with LRPPRC–dasatinib mechanism validation and practical assay design.

• YTHDF1 Phase Separation in SSC Fate Transition

  2026-08-25

  Fang et al. show that liquid-liquid phase separation by the m6A reader YTHDF1 promotes direct conversion of spermatogonial stem cells into neural stem cell-like cells. The work connects YTHDF1 condensates to selective suppression of IκBα/β mRNA translation and activation of the IκB–NF-κB–CCND1 axis, providing a mechanistic framework for studying RNA-mediated cell-fate transitions.

• Metabolic Intervention for Ferroptosis and Cuproptosis

  2026-08-25

  The 2024 Chemical Engineering Journal study develops a copper-based liposome nanosystem that combines glycolysis and NAD+ metabolic intervention with copper delivery to sensitize tumors to ferroptosis and cuproptosis. By weakening antioxidant capacity, ATP-dependent copper export, and tumor metabolic support, the strategy also promotes immunogenic cell death and antitumor immune activity.

8256 records 2/551 page Previous Next 12345 下5页 Last page